Predicting COVID-19 malignant progression with AI techniques

Xiang Bai; Cong Fang; Yu Zhou; Song Bai; Zaiyi Liu; Qianlan Chen; Yongchao Xu; Tian Xia; Shi Gong; Xudong Xie; Dejia Song; Ronghui Du; Chunhua Zhou; Chengyang Chen; Dianer Nie; Dandan Tu; Changzheng Zhang; Xiaowu Liu; Lixin Qin; Weiwei Chen

The age, sex, exposure, comorbidity, signs and symptoms, laboratory results measured at admission, and serial CT imaging features of patients with and without severe/critical progression were separately summarized in Tables 1, 2, and 3. In brief, comparing to the patients without severe/critical progression, the patients with severe/critical progression showed older age, more comorbidities, higher respiratory rate, inflammatory cell factors, lower albumin and fewer counts of lymphocyte, T cell, and its subsets. The patients with severe/critical progression were more likely to involve organs other than the lung. On the first available CT, no difference was found in either the distribution of involved lung or the other CT imaging features, except paving stone sign and the presence of fibrosis. However, the patients with severe/critical progression showed significantly more lesions in all lobes, more lesions of consolidation, paving stone sign and halo sign than patients without severe/critical progression when they progressed to the period of severe/critical stage. were the risk factors for severe/critical progression. However, the presence of fibrosis at CT 1 (OR 0.656, 95%CI 0.473-0.910) was the protective factor for severe/critical progression. The accuracy of the prediction is 79.2%.